174
Participants
Start Date
April 23, 2015
Primary Completion Date
November 12, 2020
Study Completion Date
November 12, 2020
PF-04518600
Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
PF-04518600
Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
PF-04518600 plus PF-05082566
Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
PF-04518600 plus PF-05082566
Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
Columbia University Medical Center - Herbert Irving Pavilion, New York
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Groupe hospitalier Pitie Salpetriere, Paris
Methodist Hospital-Pathology, Houston
The University of Texas MD Anderson Cancer Center, Houston
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate, Los Angeles
Keck Hospital of USC, Los Angeles
LAC+USC Medical Center, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
Ronald Regan Medical Center, Los Angeles
UCLA Hematology & Oncology Clinic, Los Angeles
Medical Imaging Center of Southern California, Inc., Santa Monica
Santa Monica UCLA Hematology & Oncology Clinic, Santa Monica
Hoag Memorial Hospital Presbyterian, Newport Beach
Institut Gustave Roussy, Villejuif
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
UConn Health, Pharmacy, Farmington
UConn Health, Neag Comprehensive Cancer Center, Farmington
Massachusetts General Hospital (MGH), Boston
Brigham & Women's Hospital (BWH), Boston
Beth Israel Deaconess Medical Center (BIDMC), Boston
Dana-Farber Cancer Institute (DFCI), Boston
Massachusetts General/Chelsea HealthCare Center, Chelsea
Mass General/North Shore Center for Outpatient Care, Danvers
Mass General West, Waltham
National Cancer Center Hospital East, Kashiwa
The Netherlands Cancer Institute, Amsterdam
Slotervaart Hospital/Antoni van Leeuwenhoek, Amsterdam
Erasmus MC, Rotterdam
Lead Sponsor
Pfizer
INDUSTRY